GC Green Cross MS Launches New Personal Blood Glucose Meter 'GC Fit Blood Glucose Meter'

Equipped with Hematocrit Correction Function
Enhanced Measurement Accuracy

GC Green Cross MS, a company specializing in the manufacturing of in vitro diagnostics and hemodialysis agents, announced on October 20 that it has recently received approval from the Ministry of Food and Drug Safety for its new personal blood glucose meter, the 'GC Fit Blood Glucose Meter (GGP-100)', and has officially launched it in the domestic market.

'GC Fit' is GC Green Cross MS's integrated brand for home medical devices, with the meaning of "home medical devices perfectly tailored to everyday life."

GC Green Cross MS's new personal blood glucose meter 'GC Fit Blood Glucose Meter'. GC Green Cross MS

The 'GC Fit Blood Glucose Meter', the first product released under the 'GC Fit' brand, is a personal blood glucose meter that uses fingertip capillary blood. Featuring a simple design, it meets the international standard ISO 15197 and is equipped with a hematocrit correction function to improve measurement accuracy. In addition, it addresses the issue of xylose interference that can occur in glucose dehydrogenase (GDH-FAD)-based measurement methods, thereby providing more reliable results. This improvement compensates for the shortcomings of existing products, which can produce errors when xylose is administered during tests such as gastrointestinal function examinations.

This new product was developed based on the technological capabilities of GC Green Cross Medis (formerly Ceragem Medisys), which was acquired by GC Green Cross MS. It is expected to enhance competitiveness in the global blood glucose meter market by improving accuracy and securing cost competitiveness compared to existing products. As a result, GC Green Cross MS now offers not only the existing grip-type model with a handle for user convenience but also a new film-type model.

According to the International Diabetes Federation (IDF), the number of diabetes patients worldwide is expected to increase from approximately 589 million last year to about 853 million by 2050, with the prevalence rate rising from 10.5% to 12.2%. Accordingly, demand for early diagnosis and self-management of diabetes continues to grow.

A GC Green Cross MS representative stated, "Although the adoption of continuous glucose monitoring systems (CGMS) is expanding, demand for conventional blood glucose monitoring systems (BGMS) remains strong due to the initial cost burden and usage complexity. In particular, new demand continues to flow in, especially in developing countries, so we plan to expand local production systems using the semi knock-down (SKD) method in Southeast Asia and Central and South America, and to accelerate our entry into the global market."

This content was produced with the assistance of AI translation services.